Compare Samsara Inc (IOT) vs TG Therapeutics Inc (TGTX) Price & Performance

Samsara Inc. (IOT) trades at $39.34, down 1.3% over 24 hours, with a bullish technical outlook supported by moving averages and recent price action above key support levels. The company reported strong earnings beats in recent quarters, with Q2 2026 results pending. Revenue growth is robust, projected to rise from $1.25B in 2025 to $1.7B in 2026, though profitability remains a concern with a negative net income in 2025 turning positive in 2026. Analyst sentiment is positive, with a consensus price target of $44.50.

The stock presents a growth opportunity driven by expanding AI adoption and strong institutional interest, but risks include high valuation multiples, competitive pressures in software, and execution challenges in scaling profitability. Investors should weigh the bullish analyst consensus against the company's transition to sustained earnings growth.

TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.

The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.